Stock Track | Tandem Diabetes Care Soars 5.29% Intraday on Multiple Analyst Upgrades After Strong Quarterly Results

Stock Track
02/23

Tandem Diabetes Care's stock surged 5.29% during intraday trading on Monday, extending its positive momentum from the previous session.

The sharp rise follows the company's report of better-than-expected quarterly financial results, which has prompted a wave of positive reactions from Wall Street analysts.

Several firms raised their price targets on the stock, including Truist Securities (to $27 from $24), Barclays (to $56 from $55), and Goldman Sachs (to $28 from $25). Furthermore, Lake Street made a significant move by upgrading Tandem Diabetes Care to Buy from Hold and dramatically raising its price target to $50 from $14.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10